Signal Diagnostics Agrees to Pay over $20M to Settle False Claims Act Allegations for Failing to Refund Overpayments to the HRSA Uninsured Program
Signal Diagnostics LLC (Signal) has agreed to pay the United States $20.5 million to resolve allegations that Signal violated the False Claims Act by knowingly retaining and improperly avoiding its obligations to repay the Health Resources & Services Administration (HRSA) COVID-19 Claims Reimbursement to Health Care Providers and Facilities for Testing, Treatment, and Vaccine Administration for the Uninsured...
Contenu original affiche; la traduction localisee n'est pas encore disponible.
Ce qui s'est passé
Signal Diagnostics LLC (Signal) has agreed to pay the United States $20.5 million to resolve allegations that Signal violated the False Claims Act by knowingly retaining and improperly avoiding its obligations to repay the Health Resources & Services Administration (HRSA) COVID-19 Claims Reimbursement to Health Care Providers and Facilities for Testing, Treatment, and Vaccine Administration for the Uninsured...
Pourquoi c'est important
The development may change operating conditions or market expectations around Regulation. Further confirmation and measurable outcomes matter.
Entités concernées
Voir les preuves
1 articles · 1 publication d'origine · 1 independantes
- U.S. Department of JusticeSource primaire · Confirme · EN · 100%Signal Diagnostics Agrees to Pay over $20M to Settle False Claims Act Allegations for Failing to Refund Overpayments to the HRSA Uninsured Program ↗
Affirmations
- Signal Diagnostics Agrees to Pay over $20M to Settle False Claims Act Allegations for Failing to Refund Overpayments to the HRSA Uninsured Program Observé
Divergences
Aucune divergence importante détectée dans les preuves disponibles.
Chronologie
- Premier signalement
Mouvement de marché suivant l'événement
La réaction du marché n'est pas encore disponible pour cet actif et cette fenêtre.